Diagnosis and Management of Vascular Ehlers-Danlos Syndrome: Experience of the UK National Diagnostic Service, Sheffield

    Jessica Bowen, Mónica Hernández Alava, Diana Johnson, Claire Green, Tammy Kammin, Duncan Baker, Sylvia Keigwin, Seiko Makino, Naomi Taylor, Oliver Watson, Nigel Wheeldon, Glenda Sobey
    Image
    Studysummary This retrospective study observed that patients with vascular EDS on long-term angiotensin II receptor blockers or beta-blockers experienced fewer vascular events compared to those without cardiac medication under similar lifestyle and emergency care advice.
    Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
    Over a 12-year period, the UK EDS National Diagnostic Service diagnosed and managed over 200 patients with vascular Ehlers-Danlos syndrome (vEDS), a rare connective tissue disorder. The study found that 40% of these patients experienced 165 vascular events, and 13.88% had bowel perforation. In terms of pregnancy, 10% of women had a life-threatening or fatal vascular event. The study also found that patients on a combination of losartan and bisoprolol had a significantly lower clinical progression score, suggesting a reduction in vascular events from this therapy. Survival in the treated group was 93.3% over a median of 4.67 years. The study emphasizes the importance of early diagnosis, lifestyle advice, and regular imaging surveillance for managing vEDS. The phenotypic spectrum of vEDS is broader than previously recognized, with early clinical signs such as significant easy bruising, severe talipes, premature birth, amniotic band sequence, distal contractures, pneumothorax, and early onset varicose veins. The study underscores the role of specialist services in managing vEDS and the need for early diagnosis for improved survival and quality of life.
    Discuss this study in the Community →